Presented Abstracts Based on NCDR® Registries
<table>
<thead>
<tr>
<th>Registry</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>CATHPCI REGISTRY®</td>
<td>1</td>
</tr>
<tr>
<td>CHEST PAIN-MI REGISTRY®</td>
<td>13</td>
</tr>
<tr>
<td>ICD REGISTRY™</td>
<td>19</td>
</tr>
<tr>
<td>CARE REGISTRY®</td>
<td>24</td>
</tr>
<tr>
<td>PINNACLE REGISTRY®</td>
<td>26</td>
</tr>
<tr>
<td>PVI REGISTRY™</td>
<td>30</td>
</tr>
<tr>
<td>IMPACT REGISTRY™</td>
<td>31</td>
</tr>
<tr>
<td>STS/ACC TVT REGISTRY™</td>
<td>31</td>
</tr>
<tr>
<td>DIABETES COLLABORATIVE REGISTRY®</td>
<td>34</td>
</tr>
</tbody>
</table>
1. 391: Use and Effectiveness of Manual Aspiration Thrombectomy during Percutaneous Coronary Intervention for the Treatment of ST-Elevation Myocardial Infarction in the US: An Analysis from the NCDR CathPCI Registry. E. Secemsky. **ACC 18 Poster Presentation**

2. 426: Current Landscape of Hybrid Revascularizations: A Report from the National Cardiovascular Data Registry. A. Lowenstern. **ACC 18 Moderated Poster Presentation**

3. 440: Ad Hoc Percutaneous Coronary Intervention in Patients with Stable Coronary Artery Disease: A Report from the National Cardiovascular Data Registry. K. Faridi. **ACC 18 Poster Presentation**

4. 419: Comparison of Rates of Bleeding and Vascular Complications Before, During, and After Trial Enrollment in the SAFE-PCI Trial for Women. J. Rymer. **ACC 18 Poster Presentation**


6. 516: Use and Effectiveness of Manual Aspiration Thrombectomy During Primary Percutaneous Coronary Intervention For the Treatment of ST-Elevation Myocardial Infarction in the United States: An Analysis From the NCDR CathPCI Registry. E. Secemsky. **ACC 18 Poster Presentation**

7. 156: Costs Associated with Trans radial Primary PCI among Elderly Patients with STEMI in the Medicare Fee-For-Service Beneficiaries A. Amin. **ACC 2017**


10. 230: Clinical Characteristics and Outcomes in patients undergoing PCI to LIMA grafts: a study from the ACC NCDR CathPCI registry K. Yeo. **TCT 2016 Poster**


14. 303: Patterns of Use and Outcomes of Antithrombotic Therapy in End Stage Renal Disease Patients Undergoing PCI: Observations from NCDR. J. Washam. **AHA 2016 Poster**

15. 248: Effectiveness of Bivalirudin Versus Unfractionated Heparin During Percutaneous Coronary Intervention Among Patients with Acute Myocardial Infarction in the United States. R. Yeh. **ACC 2016 Oral Presentation**


17. 354P/138: The Impact of Bleeding Avoidance Strategies on Hospital-Level Variation in Bleeding Rates Following Percutaneous Coronary Intervention: Insights from the NCDR CathPCI Registry. A. Vora. **ACC 16 Oral Poster Presentation**

19. 168: TOP PCI Mortality Abstract: Associations of Hospital Strategies and 30-Day Risk-Standardized Mortality Rates in Percutaneous Coronary Intervention

20. 168: Top PCI Readmission Abstract: Associations of Hospital Strategies and 30-Day Risk-Standardized Readmission Rates in Percutaneous Coronary Intervention


27. 492P-A: Correlation Among Hospital PCI Process Measures and Relationship with 30-day PCI Readmission and Mortality. P. Chui. AHA 2014 Oral Presentation.

28. 492P-B: Performance of hospitals on PCI metrics and correlation with 30-day re admissions. P. Chui. AHA 2014 Oral Presentation.


32. 452P: The Association Between Change in Hospital-Level Use of Trans radial PCI and Periprocedural Outcomes: Insights from the NCDR. S. Bradley. QCOR 2014 Poster Presentation.


35. 448P: Length of Hospital Stay and Associated Clinical Outcomes in Elderly Patients Following Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: A Report from the National Cardiovascular Data Registry®. R. Swaminathan. ACC 2014 Poster Presentation.

36. 468P: Trends in Uptake and In-Hospital Outcomes with 2nd Generation Drug Eluting Stents Between Men and Women Undergoing PCI: Results from the CathPCI Registry. U. Baber. ACC 2014 Poster Presentation.

37. 318P: Are “All-Comer” Clinical Trials Representative of Contemporary Clinical Practice: A Linked Analysis of the Dual Antiplatelet Therapy (DAPT) Study and the National Cardiovascular Data Registry. R. Yeh. AHA 2013 Poster Presentation.


45. 409P: Large Variation in Contrast Use during PCI – An Important Opportunity for Improving Contrast-induced acute kidney injury Outcomes. A. Amin. QCOR 2013 Oral Presentation.


48. 442P: Trans-radial PCI is associated with lower readmission rates for Medicare fee-for-service beneficiaries following elective PCI. M. Patterson. ACC 2013 Poster Presentation.

49. 403P: Gaps in referral to cardiac rehabilitation after percutaneous coronary intervention in the United States: insights from the National Cardiovascular Data Registry. K. Aragam. ACC 2013 Poster Presentation.


52. 393P: Trans radial PCI Is Associated with Lower Cost in Medicare Fee-for-Service Beneficiaries following Elective PCI. A. Amin. ACC 2013 Oral Presentation.


55. 365P: Percutaneous Coronary Intervention in Older Patients with Syncope and Significant Coronary Artery Disease. L. Anderson. ACC 2013 Poster Presentation.

56. 300P: The Effect of Insurance Status on Time to Percutaneous Coronary Intervention for Patients with ST Elevation Myocardial Infarction: Findings from the CathPCI Registry. A. Herring. ACC 2013 Oral Presentation.


60. 367P. Patient Selection for Bare Metal Stent Placement and Associated Longitudinal Outcomes Before and After the FDA Drug Eluting Stent Advisory. R. Harrison. AHA 2012 Oral Presentation.
61. 357P: Do Interventional Cardiology Training Programs Have Worse Outcomes Early in the Academic Year? An Assessment of the “July Effect” from the National Cardiovascular Database Registry. B. Hawkins. AHA 2012 Oral Presentation.
68. 331P: Hospital PCI Appropriateness and In-Hospital Procedural Outcomes: Insights from the NCDR®. S. Bradley. Winner: 2012 QCOR Young Investigator Award.
71. 325P: Non-System Reasons for Delay in Door-To-Balloon Time and Associated In-hospital Mortality Outcomes. R. Swaminathan. ACC 2012 Poster Presentation.
73. 306P-A: Gender Differences in the Use and Effectiveness of Bleeding Avoidance Strategies Following PCI. S. Doughert. ACC 2012 Oral Presentation.
75. 286P: Practice Comparisons Between Japan and the United States - Early Results with Japanese Percutaneous Coronary Intervention Registry and Its Direct Comparison with the Cath/PCI Registry®. S. Kohsaka. ACC 2012 Poster Presentation.
81. 341P-B: Hospital Variation in Bleeding Complications Following Percutaneous Coronary Intervention (PCI): Results from the National Cardiovascular Data Registry (NCDR). E. Peterson. AHA 2011 Oral Presentation.


84. 311P: Practice patterns of DES use as a function of restenosis risk: Results from the ACC NCDR CathPCI Registry. A. Amin. AHA 2011 Oral Presentation.


89. 10P: Clinical Strategies and Bleeding Outcomes in Elderly Patients Undergoing Primary PCI: Results from the NCDR CathPCI Registry. J. Dodson. QCOR 2011 Poster Presentation.

90. 283P-C: Temporal Shifts in Antithrombotic Therapy Help Explain Reduction in Bleeding Complications Among Patients Undergoing Percutaneous Coronary Intervention: Results from A Report from the National Cardiovascular Data (NCDR) CathPCI Registry. S. Subherwal. QCOR 2011 Oral Presentation.


94. 248P: Left-Dominant Coronary Artery Circulation is Associated with Higher In-Hospital Mortality Among Patients Undergoing Percutaneous Coronary Intervention in Acute Coronary Syndrome: Data from the American College of Cardiology National Cardiovascular Data Registry for Catheterization Percutaneous Coronary Intervention. S. Parikh. ACC 2011 Oral Presentation.


100.215P-B: Contemporary Risk of Adverse Events in Older Patients with Chronic Kidney Disease and Dialysis Undergoing Percutaneous Coronary Interventions: A Report from the Merged NCDR CMS Database. T. Tsai. AHA 2010 Oral Presentation.


112.226P (E): Comparative Effectiveness of Radial Access and Bivalirudin on PCI-Related Bleeding Events: Analysis from the National Cardiovascular Data Registry. S. Marso. Poster Presentation. i2 2010.


115.216P (B): Renally Cleared Anti-Thrombotic Agents Among Dialysis Patients Receiving Percutaneous Coronary Interventions: Insights From the ACC-NCDR Cath-PCI Registry. T. Tsai. AHA 2009 Oral Presentation. Finalist for Young Investigator Award [YIA].


118.192P: In-hospital Outcomes following No-Reflow Phenomenon after Percutaneous Coronary Intervention in Acute Coronary Syndromes. A. Aggarwal. AHA 2009 Oral Presentation.


120.181P: Annual case volume is not a strong predictor of bleeding complications after percutaneous coronary intervention: A report from the National Cardiovascular Data Registry. S. Rao. ACC 2009 Poster Presentation.

121.197P: Secondary Prevention Therapies among Patients with Non-Obstructive CAD: Insights from the NCDR CathPCI Registry. T. Maddox. ACC 2009 Nominee: Young Investigator’s Award.

123. 215P [A2]: Outcomes Following Coronary Stenting in a Linked ACC-NCDR and CMS Database: A National Study of Long Term Real-World Outcomes of Bare-Metal and Drug-Eluting Stents.  i2 '09 Late-Breaking Clinical Trial Contribution.


125. 124P: A Clinical Risk Prediction Tool for Post-PCI Bleeding from the National Cardiovascular Data Registry. Mehta.  i2 2009 Poster.

126. 211P: Comparison of Angiographic Findings and Door to Balloon Times at Hospitals that Do and Do Not Allow ED Cath Lab Activation: Insights from the NCDR CathPCI Registry and the D2B Alliance. R.C. Regan.  i2 2009 Oral Contribution.


128. 07P: Interaction of Age and Glomerular Filtration Rate to Predict In-Hospital Mortality Following Percutaneous Coronary Intervention for Acute Myocardial Infarction. Cardarelli.  AHA 2008.


132. 174P: Do Hospitals that Improve “Walk In” Door-to-Balloon Times for Primary Percutaneous Coronary Intervention Also Improve “Transfer In” Door-to-Balloon Times? Tracy Y. Wang.  AHA 2008.


134. 40P: Changing Guidelines May Affect Assessments of Quality of Care for Patients Undergoing PCI. Grace A. Lin.  ACC 2008.


147. 130P: Are we meeting the goals? Gender Analysis of Evidence Based Medical Therapies among patients presenting with an Acute Coronary Syndrome (ACS) who undergo Post-Percutaneous Coronary Intervention (PCI): Results from the ACC-NCDR Cath/PCI Registry. Nausheen Akhter. AHA 2007.


152. 124P: Incidence and Predictors of Mortality Among Patients Undergoing Rescue Percutaneous Coronary Intervention after Failed Fibrinolysis for ST-Elevation Myocardial Infarction. Sukesh C. Burjonroppa. AHA 2007; 124P.


154. 123P: The Use of Percutaneous Coronary Intervention in Patients with Class I Indications for Coronary Artery Bypass Graft Surgery: Data from the National Cardiovascular Data Registry. Andrew D Frutkin. AHA 2007.


158. 138P: Validation of Mayo Clinic Risk Adjustment Model for In-Hospital Mortality following Percutaneous Coronary Interventions using the American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR). Mandeep Singh. AHA 2007.


160. 012P: PCI in Asymptomatic Outpatients Undergoing Cardiac Catheterization: Results from the American College of Cardiology—National Cardiovascular Data Registry. JP Curtis. AHA 2006.

161. 10P: Lower Procedural Success and Higher Complications in Octogenarians with STEMI Referred for Emergency Cardiac Catheterization: Results from the American College of Cardiology—National Cardiovascular Data Registry. JP Curtis. AHA 2006.
162.08P: Effect of Insurance Status on Use of Drug-Eluting Stents versus Bare Metal Stents in Patients Undergoing Elective Percutaneous Coronary Intervention. R Vicuna. AHA 2006.


164.05P: Post-Procedural Outcomes in Hispanics, Asians, American Indians, and Caucasians Following Percutaneous Coronary Intervention. AD Patel. AHA 2006.

165.04P: Race and Gender Differences in Post-Procedural Outcomes Following Percutaneous Coronary Intervention in African Americans and Caucasians. AD Patel. AHA 2006.

166.03P: Contemporary Analysis of the Association between Hospital Volume and In-Hospital Death in Patients Undergoing Percutaneous Coronary Intervention: Results from the National Cardiovascular Data Registry. BK Nallamothu. AHA 2006.

167.02P: Time-to-Reperfusion in Patients Undergoing Inter-Hospital Transfer for Primary Percutaneous Intervention in the United States: Results from the National Cardiovascular Data Registry. BK Nallamothu. AHA 2006.

168.07P: Renal Failure, In-Hospital Mortality and Unplanned Coronary Artery Bypass Grafting Among 85 Years and Older Percutaneous Coronary Intervention Patients with Non-ST Elevation and ST Elevation Myocardial Infarction: Experience from the American College of Cardiology—National Cardiovascular Data Registry. E Veledar. American Society of Nephrology 2006.

169.36P: Comparison of In-Hospital Outcomes in Diabetics and Non-Diabetics Using the Paclitaxel and Sirolimus Drug-Eluting Stents: Results from the ACC-NCDR. E Veledar. CV Quality Forum 2006.

170.32P: Relationship Between Hospital PCI Volume and In-Hospital Major Adverse Clinical Events: The ACC-NCDR Results. LW Klein. ACC 2006.

171.28P: In-Hospital Outcomes in Patients with ACS Treated with Sirolimus and Paclitaxel Drug-Eluting Stents: Experience from the ACC-NCDR Database. E Veledar. ACC 2006.


175.30P: Demographic Variations in Percutaneous and Surgical Revascularization of Unprotected Left Main Coronary Artery Stenosis: A Report from the American College of Cardiology—National Cardiovascular Data Registry. HW Huang. CRT 2006.


179.23P: On-site surgical backup as a predictor of mortality among PCI patients with STEMI, NSTEMI, or no AMI. Jovonne K Foster. AHA 2005.

180.27P: Relationship between Hospital Coronary Angioplasty Volume and In-hospital Mortality: Results from The American College of Cardiology - National Cardiovascular Data Registry. Zefeng Zhang. AHA 2005.

181.28P: Outcome of Patients 85 and Older Undergoing PCI for Chronic CAD, Non-ST elevation and ST elevation MI: Experience from the American College of Cardiology National Cardiovascular Data Registry. Emir Veledar. AHA 2005.


185.31P: Comparison of in-hospital mortality for PCI patients receiving DES comparing Sirolimus vs Paclitaxel with or without acute myocardial infarction (AMI); the American College of Cardiology National Cardiovascular Data Registry (ACC/NCDR) experience. William Weintraub. AHA 2005.


188.05P: Post-procedural outcomes of racial groups undergoing percutaneous coronary intervention - results from the American College of Cardiology - National Cardiovascular Data Registry. Patel AD. Society for Cardiovascular Angiography and Interventions 2005.

189.113P: Racial outcomes of lesion characteristics and coronary stent use on lesion success - observations from the American College of Cardiology - National Cardiovascular Data Registry. Patel AD. Society for Cardiovascular Angiography and Interventions 2005.


192.24P: Risk adjusted modeling of in hospital mortality for insulin-dependent PCI patients receiving drug eluting stents; Experience from the American College of Cardiology National Cardiovascular Data Registry (ACC-NCDR). Emir Veledar. Transcatheter Cardiovascular Therapeutics 2005.

193.21P: Severity of Coronary Disease in End-Stage Renal Disease Patients: Angiography Results from the American College of Cardiology - National Cardiovascular Data Registry. Claudine Jurkovitz. American Society of Nephrology 2005.


204.51P: Predictors of In-Hospital Outcomes of Percutaneous Coronary Intervention in Unstable Angina and Non-ST Segment Elevation Myocardial Infarction (UA/NSTEMI): A Report from the National Cardiovascular Data Registry. LW Klein. TCT 2003.

205.44P: Effect of Gender According to Age on In-Hospital Mortality in Patients with Acute Myocardial Infarction in the ACC-NCDR. SC Beinart. ACC 2003.


207.59P: Effect of Hospital Volume on PCI Outcomes in the ACC-NCDR. SC Beinart. AHA 2002.

208.57P: Relationship of Coronary Stenting and Glycoprotein IIb/IIIa Inhibitors to PCI Outcomes in Insulin-Dependent Diabetics: A Report from the American College of Cardiology—National Cardiovascular Data Registry. LW Klein. AHA 2002.


212.57P: Relationship of Coronary Stenting and Glycoprotein IIb/IIIa Inhibitors to PCI Outcomes in Insulin-Dependent Diabetics: A Report from the American College of Cardiology—National Cardiovascular Data Registry. RG Brindis. CV Quality Forum 2002.


215.52P: The Expected Rate of Normal Coronary Arteriograms in the Cardiac Laboratory. BD McCallister. ACC 2002.


218.45P: Gender Differences in Frequencies of Significant and Severe Coronary Disease in the ACC-NCDR. LJ Shaw. ACC 2002.


220.70P: Clinical Risk Score to Predict the Likelihood of LM or 3-Vessel CAD for Patients in the ACC-NCDR. R Gibbons. AHA 2001.

222.72P: Which is more important in measuring a PCI patient's risk of adverse outcomes, clinical state or lesion classification? RJ Krone. AHA 2001.


224.75P: NO - Quality is More Important than Quantity. HV Anderson. TCT 2001.


229.78P: The Influence of Age on the In-Hospital Outcome of PCI: Results from the ACC-NCDR HV Anderson. AHA 2000.


2. 261: A. Fanaroff. Association Between Critical Care Unit Utilization and Long-Term Outcomes Among Initially Stable Patients With Non-ST Segment Elevation Myocardial Infarction. AHA 18 Moderated Poster Presentation

3. 178: B. Rodwin. Hospital variation in antiplatelet agents after myocardial infarction, an analysis of the NCDR ACTION Registry-GWTG. AHA 18 Moderated Poster Presentation

4. 265: J. Wasfy. Predicting the Need For Skilled Nursing Facilities After Acute Myocardial Infarction. ACC 18 Poster Presentation

5. 274: J. Shavadia. Association of Pre-Activation of the Cardiac Catheterization Laboratory on Reperfusion Timing Metrics For Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Report From Action Registry® ACC 18 Moderated Poster Presentation

6. 141: J. Rymer. Characteristics of Patients and Hospitals Utilizing Non-Physician Providers for Post-Myocardial Infarction Outpatient Care. QCOR 17 Moderated Poster Presentation

7. 196: S. Mikesell. Rural Systems of Care: Real World Observations and Trends in STEMI Patient Characteristics, and correlations of arrival mode to outcomes. QCOR 17 Poster Presentation

8. 190: C. Fordyce. Hospital variation in targeted temperature management for acute myocardial infarction patients complicated by out-of-hospital cardiac arrest in the U.S. ACC 17 Poster Presentation

9. 133: S. Basra. Contemporary Patterns of Ticagrelor use in Patients with Acute Myocardial Infarction: Insight from the National Cardiovascular Data Registry (NCDR). ACC 16 YIA Poster and Oral Presentation

10. 133: S. Basra. Contemporary Patterns of Ticagrelor use in Patients with Acute Myocardial Infarction: Insight from the National Cardiovascular Data Registry (NCDR). QCOR 2016 Oral Presentation


14. 156: A. Pandey. Relationship between the CMS 30-day readmission rates for acute myocardial infarction patients and their quality of care and outcomes across NCDR-ACTION/GWTG participating centers. AHA 16 Poster Presentation

15. No RPA: Padigipati. Smoking Cessation medication use after acute MI. AHA 16 Poster Presentation

16. 143: A. Fanaroff. A risk model to predict need for ICU utilization in patients with NSTEMI. AHA 16 Poster Presentation

17. 101: P. Mody. Impact of In-Hospital Acute Kidney Injury on Discharge Medications and Long-term Outcomes in Patients presenting with Myocardial Infarction. AHA 16 Poster Presentation
18. 122: M. Badri. Association Between Pre-Catheterization Use of P2Y12 Inhibitors with Timing of CABG, Occurrence of CABG-related Adverse Outcomes and In-hospital Mortality in Patients Presenting with NSTEMI and Requiring Surgical Revascularization: Insights From NCDR. ACC.16 Poster Presentation


20. 126: M. Kontos. Association of Acute Myocardial Infarction Cardiac Arrest Patient Volume and In-Hospital Mortality.

21. 134: N. Smilowitz. In-hospital mortality of myocardial infarction by sex, age, and obstructive coronary artery disease status in the ACTION Registry-GWTG. ACC 2016 Oral Presentation

22. 142a: W. Wang. Ezetimibe use as an adjunct to statin therapy after myocardial infarction: Insights from the ACTION Registry-Get with The Guidelines and Medicare Linked Database. ACC.16 Poster Presentation

23. 142b: W. Wang. Post-discharge use of statin and lipid testing after myocardial infarction QCOR 2016 Oral Presentation

24. 143: A. Fanaroff. Intensive Care Unit Utilization Among Patients Over Age 65 with Non-ST-Segment Elevation Myocardial Infarction ACC 2016 Oral Presentation

25. 137: Yi Pi. Utilization, Characteristics, and In-Hospital Outcomes for Patients with ST-Elevation Myocardial Infarction Undergoing in Hospital Coronary Artery Bypass Grafting (CABG) ACC 2016 Poster Presentation

26. 158: N. Desai. Hospital Performance on the NCDR ACTION Registry-GWTG “All-or-None Composite Measure ACC 2016 Oral Presentation

27. 186: A. Bagai. Temporal Trends in Treatments and Outcomes of Dialysis Patients with Acute Myocardial Infarction: A Report from the National Cardiovascular Data Registry

28. 81A: J. Udell. Socioeconomic Disparities in Acute Myocardial Infarction Hospital Care in the National Cardiovascular Data Registry. ACC 2015 Oral Presentation.


34. 160A: A. Bagai. In-Hospital ADP Receptor Inhibitor Switching in Myocardial Infarction Patients Treated with Percutaneous Coronary Intervention: Insights from the National Cardiovascular Data Registry®. AHA 2014 Oral Presentation.

35. 142A: J. Enriquez. The Association of Electronic Health Record Use with Acute MI Quality of Care and Outcomes: Results from the NCDR®. AHA 2014 Oral Presentation.

37. 147A: W. Karrowni. The Association of Home Warfarin Therapy with Acute Treatment Patterns and Bleeding Risk in Patients Presenting with ST-Elevation Myocardial Infarction: Results from the NCDR®. AHA 2014 Poster Presentation.

38. 151A: B. Mumma. Effects of Pre-Hospital ECG Use and Patient Residence Distance from PCI Center on Time to Device Activation in ST Segment Elevation Myocardial Infarction: A Retrospective Analysis from the NCDR. AHA 2014 Oral Presentation.


40. 144A: A. Beatty. Trends in Cardiac Rehabilitation Referral after Myocardial Infarction: Data from the National Cardiovascular Data Registry (NCDR®). QCOR 2013 Poster Presentation.


44. 134A: Frequency and Impact of Prior Myocardial Infarction among Patients with Acute Myocardial Infarction Treated in Contemporary Practice: Results from the NCDR®. L. Shen. ACC 2013 Poster Presentation.

45. 139A: Rates of Use of Medical Management Across US Hospitals for Patients with Non-ST-Elevation Myocardial Infarction and Multi-Vessel Coronary Artery Disease. R. Harskamp. ACC 2013 Poster Presentation.


50. 123A-B: Clinical Characteristics and Outcomes of Patients with Insulin Receiving and Non-Insulin Receiving Diabetes Mellitus Presenting with Myocardial Infarction: An Analysis from The NCDR® ACTION Registry. T. Rousan. AHA 2012 Poster Presentation.


54. 100A: Association of Chronic Lung Disease with Treatments and Outcomes of Acute Coronary Syndromes: Results from the NCDR®. J. Enriquez. QCOR 2012 Poster Presentation.


59. 110A: Clinical Trial Participation After Acute Coronary Syndrome and Clinical Outcomes-Insight from the NCDR. J Udell. ACC 2012 Poster Presentation.

60. 116A: Race and Sex Differences in Management and Outcomes of Patients after ST-Elevation and Non-ST-Elevation Myocardial Infarct: Results from the NCDR®. E Anstey. ACC 2012 Poster Presentation.


63. 101A: Low Levels of High-Density Lipoprotein Cholesterol (HDL-C) at Presentation in Acute Coronary Syndromes (ACS) and its Relation to Angiographically-Observed Atherosclerotic Burden: Results from the NCDR®. Acharjee. AHA 2011 Oral Presentation.

64. 20A: Characteristics and Outcomes of Emergency Department Patients Treated with Thienopyridines: Results from the NCDR®. D. Diercks. ACC 2011 Oral Presentation.


66. 64A/28A: Patterns of Care Among of Patients at High Risk for Ischemic and Bleeding Events after NSTEMI – Insights from the NCDR-ACTION Registry. N. Desai. ACC 2011 Oral Presentation.


68. 28A: Patterns of Care Among of Patients at High Risk for Ischemic and Bleeding Events after NSTEMI – Insights from the NCDR-ACTION Registry. N. Desai. ACC 2011 Oral Presentation.

69. 60A: Comparison of the Prognostic Implications of Peak CK-MB and Troponin Levels Among Patients with Acute Myocardial Infarction. CT Chin. AHA 2010 Poster Presentation.

70. 25A: Association between Natriuretic Peptides and Mortality among Patients Admitted with Myocardial Infarction in the ACTION Registry-GWTG. B. Scirica. AHA 2010 Poster Presentation.


76. 66A: Characteristics and In-hospital Outcomes of Patients with Non-ST-Segment Elevation Myocardial Infarction and Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention. E. Hanna. AHA 2010 Poster Presentation.

78. 69A: Self Transport versus Emergency Medical Service (EMS) for Patients with STEMI: Updated findings from National Cardiovascular Data Registry ACTION – Get with The Guidelines. R. Mathews. AHA 2010 Oral Presentation.


80. 59A: Differences in Practice Patterns and Outcomes between Hispanics and Non-Hispanic Whites Treated for ST-Segment Elevation Myocardial Infarction: Results from ACTION Registry – Get with The Guidelines. L. Guzman. AHA QCOR 2010 Poster Presentation.

81. 62A: Longer Hospital Length of Stay in Non-ST-Elevation Myocardial Infarction Associated with Higher Risk but Less Evidenced-Based Treatment: Results from ACTION Registry. R. Lopes. AHA QCOR 2010 Poster Presentation.

82. 68A: Hemoglobin A1c and In-hospital Mortality in patients presenting with Acute Coronary Syndrome. V. Aggarwal. AHA QCOR 2010 Poster Presentation.


86. 46A: New or presumed new left bundle branch block in patients with acute myocardial infarction: Findings from ACTION Registry-GWTG. KK Yeo. ACC 2010 Poster Presentation.

87. 60A: Comparison of the Prognostic Implications of Peak CK-MB and Troponin Levels Among Patients with Acute Myocardial Infarction. C. T. Chin. ACC 2010 Poster Presentation.


89. 08A: Delays in Emergency Department Fibrinolysis as Primary Reperfusion Therapy for Acute ST-elevation Myocardial Infarction. S. Glickman. AHA 2009 Oral Presentation.

90. 29A: Quality of Antithrombotic Management Among STEMI Patients Treated for Primary Percutaneous Coronary Intervention. T. Wang. QCOR 2009 Poster Presentation.


92. 17A: Timing of In-Hospital CABG in Relationship to Mortality for ACS Patients: Results from the NCDR ACTION Registry. J. de Lemos. ACC 2009 Oral Presentation.

93. 22A (#1): Is Pre-Existing Coronary Disease a Risk Factor for In-Hospital Mortality? An Analysis from The NCDR ACTION-GWTG Registry. M. Kontos. ACC 2009 Poster Presentation.


102.06A: Decline in the Use of Drug-Eluting Stents for Patients with Non-ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention - Results from the CRUSADE and ACTION Registries. M Roe. ACC 2008.

103.12A: Short-term Outcomes of STEMI and NSTEMI in Patients with Chronic Kidney Disease: A Report from the National Cardiovascular Data ACTION Registry. C. Fox. ACC 2008.


106.21A: Early use of beta-blockers (BB) is a quality indicator for the treatment of patients (pts) with ST-segment elevation (STEMI) and non-ST-segment myocardial infarction (NSTEMI), despite limited randomized clinical trials data. However, data from the recent COMMIT trial found an early hazard with BBs in this setting, especially for pts with high-risk features. Kontos. ACC 2008.

107.205: Frailty and Mortality in Older Patients with Acute Myocardial Infarction: Observations from the NCDR ACTION Registry-GWTG. Udell. Poster AHA 17.

108.214: The Association of Frailty with In-Hospital Bleeding Among Older Adults with Acute Myocardial Infarction: Insights from the Action Registry-GWTG. Dodson. Poster AHA 17.


111.265: Predicting the Need for Skilled Nursing Facilities After Acute Myocardial Infarction. Wasfy. Poster ACC 18.

TOC


6. 101: D. Friedman. Early use of the subcutaneous implantable cardioverter defibrillator in the United States: A report from the National Cardiovascular Data Registry. ACC 2016 Oral Presentation

7. 96: J. Betz. Outcomes of Older Survivors of Sudden Cardiac Death Receiving Secondary Prevention Implantable Cardioverter Defibrillators - An Analysis from the NCDR ICD Registry. Accepted at QCOR 2015, but never presented because conference was canceled.


9. 73: M. Gleva. Implantable Cardioverter Defibrillators in Adults with Congenital Heart Disease: Insights from the NCDR®. HRS 2015 Poster Presentation.


11. 79: D. Friedman. Comparative Effectiveness of Cardiac Resynchronization Therapy with Defibrillator versus Defibrillator Alone in Heart Failure Patients with Moderate to Severe Chronic Kidney Disease. ACC 2015 Poster Presentation.


14. 59B: R. Zusterzeel. Women have Better Survival than Men with Cardiac Resynchronization Therapy in Left Bundle Branch Block: An Observational Comparative Effectiveness Study from the National Cardiovascular Data Registry. AHA 2014 Oral Presentation.


17. 59B: R. Zusterzeel. Sex-Specific Mortality Risk by QRS Morphology and Duration in Patients Receiving Cardiac Resynchronization Therapy: Results from the NCDR®. ACC 2014 Poster Presentation.


20. 75: P. Khazanie. Use and Comparative Effectiveness of Cardiac Resynchronization Therapy Among Patients with Heart Failure and Atrial Fibrillation: Data from the NCDR-ICD Registry. ACC 2014 Poster Presentation.

21. 52: P. Khazanie, Clinical Effectiveness of Cardiac Resynchronization Therapy Compared to Medical Therapy Alone Among Patients with Heart Failure: An Analysis of the ICD and ADHERE National Registries. AHA 2013 Poster Presentation.


27. 57B: Hsu. Coronary Sinus Dissection from Cardiac Resynchronization Therapy Implantation and Associated In-Hospital Adverse Events: Insights from the NCDR®. HRS 2013 Poster Presentation.


32. 57B: Cardiac Perforation from Implantable Cardioverter-Defibrillator Lead Placement and In-Hospital Adverse Events and Mortality: Insights from the NCDR®. J. Hsu. ACC 2013 Oral Presentation.

33. 66: Building a risk model from the NCDR ICD registry for in-hospital adverse outcomes following ICD implantation. J. Dodson. ACC 2013 Poster Presentation.

34. 46: Impact of Gender on Intermediate-Term Outcome of Patients with Single or Dual Chamber Cardioverter Defibrillators Implanted for Primary Prevention: Analysis of the NCDR ICD Registry. A. Russo. AHA 2012 Oral.


37. Lead Revision is Associated with Increased Complications in Patients Undergoing Implantable Cardioverter-Defibrillator Implantation. S. Wei. HRS 2012 Poster Presentation.


41. Low Body Mass Index is Associated with In-Hospital Adverse Events and Mortality Among Implantable Cardioverter-Defibrillator Recipients Enrolled in the NCDR Implantable Cardioverter-Defibrillator Registry. J Hsu. ACC 2012 Poster Presentation.


44. Low Body Mass Index is Associated with In-Hospital Adverse Events and Mortality Among Implantable Cardioverter-Defibrillator Recipients Enrolled in the NCDR Implantable Cardioverter-Defibrillator Registry. J Hsu. Bay Area Research Symposium 2011 Poster Presentation.


50. Distribution of Risk and Potential Benefit of ICDs among primary prevention patients in the U.S. V. Tsai. NRSA 2010 Poster Presentation.


54. 36: Discretionary Use of Dual Lead Implantable Cardioverter-Defibrillators (ICDs) by Hospitals. D. Matlock. QCOR 2010 Poster Presentation.

55. 5: The Relation between Hospital Procedure Volume and Complications of Cardioverter-Defibrillator Implantation from the National Cardiovascular Data Registry. M. Hlatky. ACC 2010 Oral Presentation.

56. 24: Blood Pressure, BUN, Creatinine, Congestive Heart Failure and Cardiac Arrest (B2C3 Score) Predicts Procedure Mortality for Elective ICD Implantation: Data from the ICD Registry(TM). D. Haines. ACC 2010 Poster Presentation.

57. 35: Impact of the Medtronic Fidelis lead recall on utilization of implantable cardioverter defibrillators: Data from the NCDR ICD Registry. P. Bhatt. ACC 2010 Poster Presentation.


60. 22: Prevalence and Predictors of "Off-label" use of Cardiac Resynchronization Therapy in Patients Enrolled in the NCDR ICD Registry. M. Reynolds. AHA 2009 Poster Presentation.

61. 2: Factors Influencing the Use of Higher-Tech/Higher Cost Implantable Cardioverter-Defibrillators: Data from the NCDR ICD Registry. R. Lampert. AHA 2009 Poster Presentation.

62. 17: Regional Variations of Primary Prevention Implantable Cardioverter-Defibrillators: Results from the National Cardiovascular Data Registry (NCDR). Matlock, Masoud. ACC 2009 Oral Presentation.

63. 18: Clinical Characteristics of Patients with End Stage Renal Disease on Dialysis Referred for Implantable Cardioverter Defibrillator Implantation. A. Aggarwal. ACC 2009 Oral Presentation.

64. 1: System Level Contributions to Disparities in Cardiac Resynchronization Therapy with Defibrillator in the ACC/NCDR ICD Registry. S. Farmer. QCOR 2009.


67. 16: Dual chamber ICD selection is associated with racial and socioeconomic disparities and increased complication rates among patients enrolled in the ACC-NCDR ICD Registry. T Dewland. AHA 2008.

68. 10-I: Patients Who Receive an Implantable Cardioverter Defibrillator for MADIT-II Criteria in Clinical Practice are Different from Patients Enrolled in MADIT-II. S Al-Khatib. AHA 2007 Oral Presentation.


70. 1B: Racial and Ethnic Differences in Nationwide Utilization of Cardiac Resynchronization Therapy. Steven A Farmer. AHA 2007.

71. 3: Differences in Implantation-Related Complications between Men and Women Receiving ICD Therapy for Primary Prevention. PN Peterson. AHA 2007.

72. 4: Sex Differences in the Characteristics of Patients Receiving ICD Therapy for Primary Prevention. SL Daugherty. AHA 2007.


74. 136: Quadripolar vs. Bipolar Left Ventricular Leads in Cardiac Resynchronization Therapy: An Analysis from the NCDR. Hakemi. Poster ACC 17.
75. 128: Outcomes Following Implantable Cardioverter-Defibrillator Generator Replacement in Patients with Recovered Left Ventricular Systolic Function: Insights From the NCDR. Thomas. Poster AHA 17.

76. 158: Predictors of Performing Defibrillation Testing Among Patients Implanted with a Subcutaneous Implantable Cardioverter Defibrillator: A Report from the National Cardiovascular Data Registry. Friedman. Poster AHA 17.

77. 186: Gender Differences in Survival with Cardiac Resynchronization Therapy Defibrillators in the NCDR ICD Registry. Bilchick. Poster AHA 17.


79. 137: Outcomes Among Medicare Beneficiary Patients with Nonspecific Intraventricular Conduction Delay versus Right Bundle Branch Block Implanted with Cardiac Resynchronization Therapy with Defibrillator: Insights From the National Cardiovascular Data Registry. Kawata. Poster ACC 18.

80. 146: Characteristics and Outcome of Pediatric Patients Who Undergo Placement of Implantable Cardioverter-Defibrillator - An Insight from the National Cardiovascular Data Registry (NCDR). Baskar. Poster ACC 18.


82. 107(1). Association Between Industry Payments and In-Hospital Procedure-Related Complication Rates Following ICD Implantation: Results from the NCDR ICD Registry. Henien. Poster AHA 18.


84. 184. Temporal Trends and Variation in the Use of Defibrillation Testing in Contemporary Practice: An Analysis of the National Cardiovascular Data ICD Registry. Borne. AHA 18.


86. 104B. Survival Benefit from the Resynchronization and Defibrillator Components of Cardiac Resynchronization Therapy Defibrillators in the NCDR ICD Registry. Bilchick. Oral Presentation AHA 18.

87. 185. Defibrillation Safety Margin Testing in Congenital Heart Disease Patients with Implantable-Cardioverter Defibrillators: Results from the National Cardiovascular Data Registry ICD Registry. Prutkin. Poster AHA 18.
**TOC**

**CARE Registry®**

1. 5-NCDR-A: Carotid Artery Stenting and Carotid Endarterectomy are Comparable Among Medicare Beneficiaries Treated in Routine Clinical Practice. J. Jalbert. **AHA 2014 Poster Presentation.**

2. 5-NCDR-B: Potential Heterogeneity in the Effectiveness of Carotid Artery Stenting vs. Carotid Endarterectomy Among Subgroups of Medicare Beneficiaries in Routine Clinical Practice. J. Jalbert. **AHA 2014 Poster presentation.**


4. 52C: Racial and Ethnic Variation in Utilization and Outcomes in Carotid Artery Revascularization: Analysis from the NCDR®. F. Lafit. **TCT 2013 Poster Presentation.**

5. 44C: Hospital Variation in Carotid Artery Stenting Outcomes- An NCDR Analysis. B. Hawkins. **QCOR 2013 Poster Presentation.**

6. 25C-B: Comparative Effectiveness of Commonly Used Devices for Carotid Stenting. J. Giri. **ACC 2012 Poster Presentation.**


8. 24C: Hemorrhagic and Ischemic Outcomes following Bivalirudin vs. Unfractionated Heparin during Carotid Artery Stenting: Analysis from the NCDR®. S. Wyangankar. **ACC 2012 Poster Presentation.**


10. 15C-B: Outcomes of CEA in the elderly in the CARE registry. K. Rajamani. **ISC 2012 Oral Presentation.**

11. 32C: Predicting In-Hospital Cardiovascular Events Following Carotid Artery Stenting: The Development of a Risk Model Using the NCDR-CARE Registry®. B. Hawkins. **SCAI 2012 Poster Presentation.**

12. 20C: Impact of timing of carotid artery stenting on outcomes in the symptomatic population. N. Ruggiero. **ACC 2011 Poster Presentation.**

13. 19C: Outcomes of Endovascular Treatment for Carotid Artery Restenosis following prior carotid artery stenting or endarterectomy. B. Hynes. **Poster Presentation AHA 2011. Best Poster of Session.**


15. 1C: Impact of Glomerular Filtration Rate on Clinical Outcomes Following Carotid Artery Revascularization in 12,304 Patients from the CARE Registry®. L. Gruberg. **AHA 2010 Oral Presentation.**

16. 17C: Clinical referral patterns for carotid artery stenting versus carotid endarterectomy: Results from the CARE registry. R. Longmore. **QCOR 2010 Poster Presentation.**

17. 9C: Influence of participation in clinical trials on outcomes after carotid artery stenting – results from the Carotid Artery Revascularization and Endarterectomy (CARE) Registry. R. Yeh. **ACC 2010 Poster Presentation.**

18. 11C (B): Carotid revascularization immediately prior to urgent cardiac surgery: Clinical outcomes associated with the choice of carotid artery stenting (CAS) or endarterectomy (CEA) from the NCDR-CARE registry. C. Don. **ACC 2010 Poster Presentation.**

19. 11C (A): Carotid revascularization immediately prior to urgent cardiac surgery: Practice patterns associated with the choice of carotid artery stenting (CAS) or endarterectomy (CEA) from the NCDR-CARE registry. C. Don. **ACC 2010 Poster Presentation.**

20. 04C: High-risk Features of Carotid Artery Stent Patients: Preliminary Results from the CARE Registry. H.V. Anderson, K. Rosenfield. **ACC 2009 Poster Presentation.**
21. 6C: Gender Differences in Short-Term Outcomes After Carotid Revascularization: The CARE Registry. N. Grootenboor. AHA 2009 Oral Presentation.

22. 13C: Relationship Between Procedure Indications and Outcomes of Carotid Artery Stenting: Preliminary Results from the CARE Registry. KA Rosenfield. AHA 2008.
TOC

PINNACLE Registry®


7. PINN-50: N. Thande. The Relationship Between Provider Experience and Cardiac Performance Measure Compliance in Outpatients: Results from the NCDR. ACC 2015 Poster Presentation.


20. PINN-43: Differences in the Compliance of Coronary Artery Disease (CAD) Performance Metrics and Statin Use in Patients who have Undergone Recent Coronary Artery Bypass Grafting (CABG) Compared to Those with Recent Percutaneous Coronary Intervention (PCI). S. Bandeali. QCOR 2013 Poster Presentation.


25. PINN-23A: Practice Level Variation in use of Recommended Medications among Outpatients with Heart Failure: A Report from the NCDR® PINNACLE Registry®. PN Peterson. QCOR 2012 Poster Presentation.

26. PINN-23B: Practice Variation is a Significant Contributor to Secondary Prevention Medication Use: Insights from the NCDR PINNACLE Program. TM Maddox. QCOR 2012 Poster Presentation.


33. PINN-6: Achievement of NCEP-Recommended Lipid Goals in Patients with Dyslipidemia: Insights from the NCDR PINNACLE Registry. SA Spinler. AHA 2011 Poster Presentation.


37. PINN-6: National Cholesterol Education Program (NCEP) Lipid Goal Achievement Beyond Low-density lipoprotein cholesterol (LDL-C) in Patients with Diabetes Mellitus (DM): Focus on Non-High-Density Lipoprotein Cholesterol (non-HDL-C) in the Practice Innovation and Cl. SA Spinler. ACCP Annual Meeting 2011.


42. PINN-2: Practice-Level Variation in Cardiac Performance Measure Compliance: Insights from the ACC’s NCDR PINNACLE Registry. Chan. AHA 2010 Poster Presentation.

43. IC3-19: Building quality improvement from the ground up: Lessons from the design and implementation of the IC3 Program national practice-based quality improvement program. M. Elma. QCOR 2010 Poster Presentation.

44. IC3-20: Implementing an Orientation and Training Program for Quality Improvement in the Office-based Setting: Initial Observations from the American College of Cardiology Improving Continuous Cardiac Care (IC3) Pilot Program Assessing the Feasibility of Implementing a Clinical Decision Support Tool in the Office-based Setting: Experiences from the American College of Cardiology’s Improving Continuous Cardiac Care (IC3) Pilot Program. K. Kehoe. QCOR 2010 Poster Presentation.


46. IC3-22: Utilization of a Clinical Registry to Drive Practice-Based Learning and Improvement among Cardiology Fellows in Training: Observations from the American College of Cardiology’s PINNACLE Registry. M. Frederick. QCOR 2010 Poster Presentation.

47. IC3-13: Building quality improvement from the ground up: Lessons from the design and implementation of the IC3 Program national practice-based quality improvement program. J. Wright. World Congress of Cardiology 2010 Oral Presentation.

48. IC3-9: Sex Differences in Outpatient Performance Measures: A Report of the first 14,000+ Patients in the American College of Cardiology’s IC3 (Improving Continuous Cardiac Care) Program. P. Chan. ACC 2010 Poster Presentation.

49. IC3-10: Racial Differences in Outpatient Performance Measures: A Report of the first 10,000+ Patients in the American College of Cardiology’s IC3 (Improving Continuous Cardiac Care) Program. P. Chan. ACC 2010 Poster Presentation.

50. IC3-11: The American College of Cardiology’s IC3 (Improving Continuous Cardiac Care) Program and Heart Failure Performance Measures: A Report of the first 14,000+ Patients. P. Chan. ACC 2010 Poster Presentation.

51. IC3-12: Outpatient Compliance with Performance Measures for Atrial Fibrillation: A Report of the first 14,000+ Patients from the American College of Cardiology’s IC3 (Improving Continuous Cardiac Care) Program. P. Chan. ACC 2010 Oral Presentation.
52. IC3-18: Feasibility of developing and implementing a national practice-based quality improvement program for quality improvement: Results from the IC3 Program pilot. F. Fiocchi. Academy Health 2010 Poster Presentation.

53. IC3-8: Electronic Medical Record Adoption in Cardiology Practices: A 2009 Snapshot from the American College of Cardiology’s IC3 (Improving Continuous Cardiac Care) Program. K. Mitchell. AHA 2009 Poster Presentation.

54. IC3-7: The American College of Cardiology’s IC3 (Improving Continuous Cardiac Care) Program: A Report of the first 10,000+ Patients. P. Chan. AHA 2009 Oral Presentation.

55. IC3-3: The role of strategic alliances as a key success factor in the development of a national quality improvement program for office-based cardiology practices in the U.S. F. Fiocchi. QCOR 2009.

56. IC3-4: Claims versus Clinical Data Conundrum: Can Two Disparate Data Sources Measure Physician Performance for the Same Purpose in the Same Way: The PQRI Registry Alternative Perspective. P. Jones. QCOR 2009.

57. IC3-5: Challenges of Implementing Cardiac Performance Measures: Insights from the IC3 Program. J. Spertus. QCOR 2009.


59. 90: Implications of the IMPROVE-IT Trial for Contemporary Cardiovascular Practice: An NCDR® Research to Practice (R2P) Project. Maddox. Poster ACC 17.

60. 93(1): Implications of the FDA approval of PCSK9 inhibitors for Contemporary Cardiovascular Practice: Findings from the NCDR® Research to Practice (R2P) Initiative. Hess. Poster ACC 17.


67. 158: Patient and Practice Characteristics Associated with Switching From Warfarin to a Direct Oral Anticoagulants in Patients with Atrial Fibrillation – An Analysis from the NCDR PINNACLE Registry. Sciria. Poster AHA 18.

68. 196. The Benchmarking an Oral Anticoagulant Treatment Rate in Patients with Nonvalvular Atrial Fibrillation (BOAT-AF) study: A prospective, multicenter study evaluating perspectives on use of oral anticoagulation using a patient survey and clinical review by the treating physician among patients not currently treated with oral anticoagulation. Cannon. AHA 18.
1. 20: A Risk Model of Acute Kidney Injury in Patients Undergoing Peripheral Vascular Intervention: From the National Cardiovascular Data Registry Peripheral Vascular Intervention (NCDR PVI) Registry™. Sefley. AHA 2018


5. IMPACT Registry™: First Review of Community Practice with respect to Aortic and Pulmonary Artery Stenting. J. Moore. ACC 2013 Poster Presentation.

6. IMPACT Registry™: First Review of Community Practice with respect to Device Closure of ASD and PDA. J. Moore. ACC 2013 Poster Presentation.


10. IMPACT Registry™: Improving Pediatric and Adult Congenital Treatment. J. Rome. World Congress of Pediatric Cardiology & Cardiac Surgery Oral Presentation (June 2009).


13. Trainee Presence in the Cardiac Catheterization Laboratory and Association with Procedural Outcomes Following Pediatric Cardiac Catheterization. N. Jayaram CHOP Poster

14. Risk of catastrophic outcome following cardiac catheterization for pulmonary hypertension: An analysis of data from the IMPACT® Registry. M. O’Byrne ACC.17 Moderated Poster

15. Risk factors for adverse events after catheter-based procedures in adolescents and adults with congenital heart disease - a report from the IMPACT registry. A. Stefanescu ESC 2016 Poster

16. Variations in practice patterns in device closure of atrial septal defects and patent ductus arteriosus: An analysis of data from the IMPACT® Registry M. O’Byrne AHA 2016 Rapid Fire Moderated Poster

17. Variability in Practice Patterns and Consistency with Published Guidelines for Aortic and Pulmonary Balloon Valvuloplasty: An Analysis of Data from the IMPACT Registry – A. Glatz AHA 2016 Rapid Fire Moderated Poster

18. Adjusting for Risk Associated with Congenital Cardiac Catheterization: A Report from the IMPACT® Registry. N. Jayaram. CHOP 2016 Poster Presentation

TOC

2. 256. 30-day outcomes of transcatheter mitral valve replacement in native mitral valve disease with severe mitral annular calcification in the United States: Data from the STS/ACC/TVT Registry. Guerrero. EuroPCR 18 Late Breaking Clinical Trial Presentation


4. 194. Incidence and Risk Factors of Aborted Procedures and Emergent Conversion to Surgery During Elective TAVR. Wang. TCT.18

5. 285. Change in Mitral Valve Gradient Following Mitraclip Repair and Correlation to 30-day and 1 year outcomes. Van Assche. TCT.18


7. 263. Incidence and Risk Factors for Early Stroke after Transcatheter Aortic Valve Replacement: Insights from the STS-ACC TVT Registry. Huded. TCT.18

8. 264. Incidence, predictors, and outcome of patients with prosthesis patient mismatch (PPM) after TAVR. Herrmann. TCT.18

9. 215. Atrial Fibrillation Is Associated With Higher Rates of Death and Heart Failure Hospitalizations in Patients Undergoing MitraClip: Outcomes From the TVT Registry. Arora ACC.18 Poster Presentation

10. 267. The Effect and Relationship of Age and Frailty on Survival in Patients Undergoing Transcatheter Aortic Valve Replacement. Kiani. ACC.18 Moderated Poster

11. 260. High Hospital Variability in Mortality After TAVR Can Be Explained by Differences in Failure to Rescue From Post Procedural Complications. Bishawi. ACC.18 Moderated Poster


13. 254. Outcomes Following Urgent/Emergent Transcatheter Aortic Valve Replacement: Insights From the STS/TVT Registry. Kolte. ACC.18 Moderated Poster

14. 256. 30-day outcomes of transcatheter mitral valve replacement in native mitral valve disease with severe mitral annular calcification in the United States: Data from the STS/ACC/TVT Registry. Guerrero. EuroPCR.18 Late Breaking Clinical Trial

15. 130. Direct-home discharge and likelihood of 30-day hospital readmission after transcatheter aortic valve replacement (TAVR): Findings from the STS/ACC TVT Registry. J. Dodson ACC.17 Poster Presentation


18. 156. Incidence and Outcomes of Patients Requiring Surgical Bail-Out during Transcatheter Aortic Valve Replacement from the NCDR® STS/ACC TVT Registry. A. Moldonado ACC.17 Moderated Poster Presentation


22. 269. Real-World Comparative Effectiveness of Transcatheter Versus Surgical Aortic Valve Replacement in the United States: An Analysis from Two US Registries Linked to Medicare Data. M. Brennan. ACC.17 Featured Clinical Research

23. 114. Impact of the Presence of Coronary Artery Disease and Timing of Revascularization on Outcomes of Patients Undergoing Trans-Catheter Aortic Valve Replacement: Insights From STS/ACC TVT Registry. H. Tankazyan. ACC.17 Poster Presentation


30. 245. Outcomes in the Commercial Use of Self-Expanding Prostheses in Transcatheter Aortic Valve Replacement: A Comparison of the Medtronic CoreValve and Evolut R platforms in the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. P. Sorajja. TCT 2016 Poster Presentation

31. 105. Outcomes of Permanent Pacemaker Implantation Following Transcatheter Aortic Valve Replacement: Analysis of the STS/ACC TVT RegistryTM. Fadahunsi. ACC 2016 Oral Presentation

32. 98. Impact of pulmonary hypertension on outcomes of patients undergoing transcatheter aortic valve replacement: Report from the TVT registry. C. Don. ACC 2016 Oral Presentation

33. 133. Transcatheter Aortic Valve Replacement is Associated with Fewer Hospital Days: A Report from the STS / ACC TVT Registry. S. Vemulapalli. ACC 2016

34. 106. Procedure Volume and Outcome for Transcatheter Aortic Valve Replacement in U.S. Clinical Practice. J. Carroll. ACC 2016 LBCT


Diabetes Collaborative Registry®


